(Q42982312)

English

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

scientific article published on December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors (English)

1 reference

Europe PubMed Central

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

10

object named as

Eiji Tanaka

1 reference

Europe PubMed Central

12 November 2017

author name string

Haruaki Shirakawa

1

1 reference

Europe PubMed Central

12 November 2017

Akihiro Matsumoto

2

1 reference

Europe PubMed Central

12 November 2017

Satoru Joshita

3

1 reference

Europe PubMed Central

12 November 2017

Michiharu Komatsu

4

1 reference

Europe PubMed Central

12 November 2017

Naoki Tanaka

5

1 reference

Europe PubMed Central

12 November 2017

Takeji Umemura

6

1 reference

Europe PubMed Central

12 November 2017

Tetsuya Ichijo

7

1 reference

Europe PubMed Central

12 November 2017

Kaname Yoshizawa

8

1 reference

Europe PubMed Central

12 November 2017

Kendo Kiyosawa

9

1 reference

Europe PubMed Central

12 November 2017

Nagano Interferon Treatment Research Group

11

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

1 December 2008

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

48

1 reference

Europe PubMed Central

12 November 2017

1753-1760

1 reference

Europe PubMed Central

12 November 2017

6

1 reference

Europe PubMed Central

12 November 2017

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Th1 response during ribavirin and interferon-alpha combination therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

21 January 2018

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

7 January 2021

based on heuristic

inferred from DOI database lookup

New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response or no response to IFN

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22543

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.22543

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42982312&oldid=1975833485"